Rhythm’s ColoSTAT delivers consistent cancer detection across ages and genders

• Rhythm’s ColoSTAT demonstrates conclusive performance in patients aged 45 to 80 diagnosed with colorectal cancer
• ColoSTAT performance consistent across both males and females
• Data indicates potentially suitable for early onset cancer in patients under 50

Special Report: Further analysis of Rhythm Biosciences’ final, validated ColoSTAT blood test for colorectal cancer continues to show strong and consistent performance across different age groups and gender.

Predictive cancer diagnostics company Rhythm Biosciences (ASX:RHY) has reported additional interpretation of results of a continued evaluation of the final, validated version of ColoSTAT on an extensive range of patients aged from 28 to 91 and both genders.

Following completion of the ColoSTAT evaluation on stage I to IV colorectal cancers, a further analysis was completed to establish whether ColoSTAT was effective across an extensive range of ages and to evaluate performance on males and females.

The latest evaluation showed that the test remains highly effective in detecting colorectal cancer across a wide age spectrum.

The company said when focussing analysis to the 188 patients aged from 45 to 84, the data showed that ColoSTAT was equally effective at detecting colorectal cancer across this age spectrum.

Importantly, ColoSTAT performed equally well in both males and females, despite known differences in survival and disease patterns between genders.

Promising results in under 50

Early data also suggests promising results in patients under 50, a demographic increasingly affected by so-called “early-onset” bowel cancer.

Rhythm said it had smaller datasets of individuals with cancer between 28 to 45 years of age and while the initial data was positive, it was determined to pursue further studies required to establish statistical significance and determine its final performance.

“This ongoing study to establish the performance of ColoSTAT across different ages and both genders is an important addition to the increasing body of clinical evidence,” clinical advisor to Rhythm Dr Andy Feber said.

“There are several other subgroups that require further study including the <50-year-olds and different ethnicities, including Indigenous Australians, and we’re excited about the opportunity to continue to build the evidence as to why ColoSTAT is an important clinical test.”

Further analysis results are expected as Rhythm advances towards commercialisation of ColoSTAT.

A domestic launch is planned following completion of the National Association of Testing Authorities, Australia (NATA) assessment.

This article was developed in collaboration with Rhythm Biosciences, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.